Skip to content

PDS Biotechnology Corp: 10-K filed 2026-03-30

What PDS Biotechnology Corp reported in its annual report filed 2026-03-30 (fiscal FY 2025): 41 published measures, 98 facts as tagged in accession 0001140361-26-012030.

This filing

Form
10-K (annual report)
Filed
2026-03-30
Fiscal period
fiscal FY 2025
Accession
0001140361-26-012030 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PDS Biotechnology Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-12-3130,494,083USD
At 2024-12-3145,358,657USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-12-3121,242,250USD
At 2024-12-3126,353,809USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-12-319,251,833USD
At 2025-09-309,453,510USD
At 2025-06-3015,959,784USD
At 2025-03-3122,362,209USD
At 2024-12-3119,004,848USD
At 2024-09-3022,000,805USD
At 2024-06-3030,917,870USD
At 2024-03-3137,183,045USD
At 2023-12-3126,130,947USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-12-3126,711,969USD
At 2024-12-3141,689,591USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-7,562,919USD92
2025-01-01 to 2025-12-31-34,495,505USD365
2025-07-01 to 2025-09-30-9,009,411USD92
2025-04-01 to 2025-06-30-9,434,208USD91
2025-01-01 to 2025-03-31-8,488,967USD90
2024-10-01 to 2024-12-31-7,952,352USD92
2024-01-01 to 2024-12-31-37,610,384USD366
2024-07-01 to 2024-09-30-10,726,658USD92
2024-04-01 to 2024-06-30-8,327,897USD91
2024-01-01 to 2024-03-31-10,603,477USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-12-31-27,752,012USD365
2024-01-01 to 2024-12-31-35,030,223USD366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-12-310USD365
2024-01-01 to 2024-12-3129,000USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-12-3112,774,390USD365
2024-01-01 to 2024-12-3120,188,297USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-12-310USD365
2024-01-01 to 2024-12-31-29,000USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-12-31-216,606,504USD
At 2024-12-31-182,110,999USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-01-01 to 2025-12-3146,384,280shares365
2024-01-01 to 2024-12-3136,452,707shares366

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-01-01 to 2025-12-3146,384,280shares365
2024-01-01 to 2024-12-3136,452,707shares366

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-01-01 to 2025-12-31-0.74USD/shares365
2024-01-01 to 2024-12-31-1.03USD/shares366

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-01-01 to 2025-12-31-0.74USD/shares365
2024-01-01 to 2024-12-31-1.03USD/shares366

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-01-01 to 2025-12-31-1,169,820USD365
2024-01-01 to 2024-12-31-869,169USD366

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-12-31120,184USD
At 2024-12-31142,020USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-12-314,106,606USD365
2024-01-01 to 2024-12-316,848,193USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-12-31-31,543,959USD365
2024-01-01 to 2024-12-31-36,321,195USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-12-3128,254,085USD
At 2024-12-3145,054,443USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-12-319,483,214USD
At 2024-12-3117,087,201USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-12-313,574,448USD
At 2024-12-311,684,868USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-01-01 to 2025-12-3131,543,959USD365
2024-01-01 to 2024-12-3136,321,195USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-01-01 to 2025-12-3119,025,832USD365
2024-01-01 to 2024-12-3122,565,524USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-12-3154,878,233shares
At 2024-12-3137,987,380shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-12-3126,711,969USD
At 2024-12-3141,689,591USD
At 2023-12-3156,560,517USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-12-31225,840,226USD
At 2024-12-31201,103,311USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-12-31295,911USD
At 2024-12-31295,911USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-12-31175,727USD
At 2024-12-31153,891USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-12-31742,227USD
At 2024-12-312,841,214USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-12-311,542,116USD
At 2024-12-313,364,852USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2025-12-3134,912USD
At 2024-12-3147,334USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-01-01 to 2025-12-31-35,665,325USD365
2024-01-01 to 2024-12-31-38,479,553USD366

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-01-01 to 2025-12-31-34,495,505USD365
2024-01-01 to 2024-12-31-37,610,384USD366

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-12-3112,518,127USD365
2024-01-01 to 2024-12-3113,755,671USD366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-12-3121,836USD365
2024-01-01 to 2024-12-3121,112USD366

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-01-01 to 2025-12-315,338,607USD365
2024-01-01 to 2024-12-314,673,174USD366

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2025-01-01 to 2025-12-31-1,169,820USD365
2024-01-01 to 2024-12-31-869,169USD366

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-12-312,921,359USD365
2024-01-01 to 2024-12-313,556,662USD366

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-01-01 to 2025-12-31-1,162,953USD365
2024-01-01 to 2024-12-31-924,158USD366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-12-319,709,064USD365
2024-01-01 to 2024-12-310USD366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-12-311,889,580USD365
2024-01-01 to 2024-12-31-5,297,956USD366

Inspect the source

Entity
PDS Biotechnology Corp / CIK 0001472091
Captured
2026-09-20T09:07:40.584Z
SEC response SHA-256
69e1cee7a201b49964a3008a5c2ec76eaaf5723c75824c2caf8a2c52d86edef2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001472091.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))